RxDoctor Payments Data

Sherell Vicks, MD

Internal Medicine · Lithonia, GANPI 1932251253

Payments from drug & device makers

$569in general payments, 2019–2025

Across 33 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$91
  • AbbVie$88
  • Otsuka America Pharmaceutical, Inc.$84
  • GSK$49
  • Boehringer Ingelheim$40
  • Novartis$39
  • plus $178 from 8 others

What the payments were for

  • Food & beverage$55497%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$569 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$2,537
Medicare patients
20
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide70$96,280
MounjaroTirzepatide67$79,832
EliquisApixaban65$61,672
OzempicSemaglutide54$61,048
TradjentaLinagliptin25$31,978
JanuviaSitagliptin Phosphate29$29,987
JardianceEmpagliflozin24$22,645
FarxigaDapagliflozin Propanediol27$20,653
JanumetSitagliptin Phos/Metformin Hcl30$20,140
LinzessLinaclotide19$16,495
GlyxambiEmpagliflozin/Linagliptin16$15,619
RybelsusSemaglutide14$13,512
MyrbetriqMirabegron12$13,222
Breo ElliptaFluticasone/Vilanterol23$12,844
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$39$176,112137 claims
Novo NordiskOzempic, Rybelsus$91$74,56068 claims
Boehringer IngelheimTradjenta, Jardiance, Glyxambi$40$70,24265 claims
MerckJanuvia, Janumet$23$50,12659 claims
GSKBreo Ellipta, Trelegy Ellipta$49$25,65535 claims
AbbVieLinzess$88$16,49519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Lithonia

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →